Figure 4From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinomaKaplan-Meier analysis of (A) overall (solid line) and progression-free (dashed line) survival of per-protocol patients treated with MVA-5T4 and IL-2. (B) Overall survival of stable (solid line) and progressive (dashed line) disease patients. Numbers of patients at risk at 8, 20 and 28 months are shown below the graph.Back to article page